Scilex Holding Company announced that the registration statement on Form S-4, related to the proposed business combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., has been declared effective by the U.S. Securities and Exchange Commission (SEC).
This regulatory approval is a crucial step towards the completion of the business combination. Denali Capital Acquisition Corp. will now hold an extraordinary general meeting of shareholders on September 3, 2025, to approve the proposed transaction.
The business combination is expected to close as soon as reasonably practicable after shareholder approvals and the satisfaction of other customary closing conditions. This event moves the spin-off of Semnur closer to realization, aiming to unlock value from the SP-102 asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.